DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone408-777-1417
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.56 million
Profitability
Miscellaneous
Employees88
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Tuesday, May, 7th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company earned $4.13 million during the quarter, compared to analysts' expectations of $3.50 million. DURECT had a negative return on equity of 108.92% and a negative net margin of 125.76%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
1 Wall Street analysts have issued 1-year price objectives for DURECT's stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate DURECT's share price to reach $3.50 in the next year. This suggests a possible upside of 380.9% from the stock's current price. View Analyst Price Targets for DURECT.
What is the consensus analysts' recommendation for DURECT?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.
Has DURECT been receiving favorable news coverage?
Headlines about DRRX stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DURECT earned a news impact score of -1.0 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Are investors shorting DURECT?
DURECT saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 3,315,037 shares, an increase of 70.5% from the March 29th total of 1,943,955 shares. Based on an average daily trading volume, of 295,610 shares, the short-interest ratio is presently 11.2 days. Currently, 2.1% of the company's stock are short sold. View DURECT's Current Options Chain.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Flexion Therapeutics (FLXN), NuCana (NCNA), BioSpecifics Technologies (BSTC), Corium International (CORI), Corbus Pharmaceuticals (CRBP), ProQR Therapeutics (PRQR), Evolus (EOLS), Vital Therapies (VTL), Albireo Pharma (ALBO), INDIVIOR PLC/S (INVVY), Achillion Pharmaceuticals (ACHN), DiaMedica Therapeutics (DMCAF), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL) and Savara (SVRA).
What other stocks do shareholders of DURECT own?
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
- Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
- Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
- Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist
Who are DURECT's major shareholders?
DURECT's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.54%), Ingalls & Snyder LLC (5.09%), Renaissance Technologies LLC (1.88%), Gagnon Securities LLC (0.85%), Tocqueville Asset Management L.P. (0.64%) and Acadian Asset Management LLC (0.57%). Company insiders that own DURECT stock include James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.
Which major investors are selling DURECT stock?
DRRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Ingalls & Snyder LLC, Jacobs Levy Equity Management Inc., Cowen Prime Services LLC, Oxford Asset Management LLP and Acadian Asset Management LLC. View Insider Buying and Selling for DURECT.
Which major investors are buying DURECT stock?
DRRX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Ironwood Investment Management LLC, Tocqueville Asset Management L.P., Gagnon Securities LLC, Ladenburg Thalmann Financial Services Inc., State of Wisconsin Investment Board, BNP Paribas Arbitrage SA and Wells Fargo & Company MN. Company insiders that have bought DURECT stock in the last two years include James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $0.7278.
How big of a company is DURECT?
DURECT has a market capitalization of $118.17 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.
What is DURECT's official website?
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (NASDAQ DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
